---
title: "Regulatory Clarity and De-Risked Phase 3 Plan Support Cadrenal Buy Rating, $13 Target Unchanged"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297637272.md"
description: "H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Cadrenal Therapeutics with an unchanged $13 price target. The decision is driven by regulatory clarity from FDA alignment on the Phase 3 design for CAD-1005, which de-risks the development path. Analysts highlight potential commercialization opportunities by 2030, though securing funding or partnerships remains a key obstacle to initiating Phase 3 trials."
datetime: "2026-09-01T10:25:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297637272.md)
  - [en](https://longbridge.com/en/news/297637272.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297637272.md)
generator: "portal-rs"
---

# Regulatory Clarity and De-Risked Phase 3 Plan Support Cadrenal Buy Rating, $13 Target Unchanged

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Cadrenal Therapeutics, Inc. today and set a price target of $13.00.

Joseph Pantginis has given his Buy rating due to a combination of factors tied to both regulatory progress and long‑term value potential. He views the recent FDA alignment on the primary endpoint and placebo‑controlled Phase 3 design for CAD-1005 in heparin-induced thrombocytopenia as a key de-risking event that clarifies the registrational path and supports a more predictable development timeline.

Pantginis also highlights that the planned interim analysis and the company’s projected path toward an NDA filing in 2029 and a potential 2030 launch underpin a meaningful commercialization opportunity, which he believes is not fully reflected in the current share price. While he acknowledges that securing adequate funding and/or a partnership remains the main obstacle to initiating Phase 3, he expects the improved regulatory clarity to enhance Cadrenal’s attractiveness to partners, justifying a continued Buy rating and an unchanged $13 price target.

### Related Stocks

- [CVKD.US](https://longbridge.com/en/quote/CVKD.US.md)

## Related News & Research

- [Cadrenal Therapeutics CEO presents at H.C. Wainwright Global Investment Conference](https://longbridge.com/en/news/297910480.md)
- [Cadrenal says Phase 2 trial of CAD-1005 cuts thrombotic events by more than 25% in HIT](https://longbridge.com/en/news/292495231.md)
- [Tyra Biosciences: Buy Rating Reiterated as SURF302 Data Upside Beckons; 12‑Month Price Target Maintained at $45](https://longbridge.com/en/news/298055291.md)
- [United Natural Foods Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call](https://longbridge.com/en/news/298041499.md)
- [These Analysts Revise Their Forecasts On Guidewire Software After Q4 Results](https://longbridge.com/en/news/298046915.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**